Somewhat Positive Media Coverage Somewhat Unlikely to Affect Ultragenyx Pharmaceutical (RARE) Share Price
Headlines about Ultragenyx Pharmaceutical (NASDAQ:RARE) have trended somewhat positive on Wednesday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ultragenyx Pharmaceutical earned a news impact score of 0.13 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.8028867048251 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern’s scoring:
- ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : November 20, 2017 (finance.yahoo.com)
- Ultragenyx Pharmaceutical Inc. to Post Q4 2017 Earnings of ($2.03) Per Share, SunTrust Banks Forecasts (RARE) (americanbankingnews.com)
- Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency (finance.yahoo.com)
- Ultragenyx Pharmaceutical Inc. (RARE) Given New $80.00 Price Target at Canaccord Genuity (americanbankingnews.com)
- Ultragenyx Pharmaceutical’s (RARE) Buy Rating Reaffirmed at Cowen and Company (americanbankingnews.com)
Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded up $0.29 during trading hours on Wednesday, hitting $48.13. The company had a trading volume of 427,000 shares, compared to its average volume of 433,275. Ultragenyx Pharmaceutical has a 1 year low of $44.02 and a 1 year high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, meeting the consensus estimate of ($1.87). The firm had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.02 million. The business’s revenue was up 81.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.64) earnings per share. analysts predict that Ultragenyx Pharmaceutical will post -7.26 earnings per share for the current fiscal year.
RARE has been the topic of a number of research reports. HC Wainwright restated a “neutral” rating and issued a $75.00 price objective (up previously from $72.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 8th. Canaccord Genuity set a $80.00 price objective on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Thursday, November 16th. Jefferies Group LLC set a $62.00 price objective on Ultragenyx Pharmaceutical and gave the company a “hold” rating in a report on Wednesday, August 23rd. Stifel Nicolaus restated a “buy” rating and issued a $85.00 price objective (down previously from $95.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, August 23rd. Finally, Evercore ISI initiated coverage on Ultragenyx Pharmaceutical in a report on Wednesday, August 16th. They issued an “in-line” rating and a $63.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $71.60.
WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-ultragenyx-pharmaceutical-rare-share-price/1719859.html.
In other news, CEO Emil D. Kakkis bought 7,500 shares of the company’s stock in a transaction on Monday, August 28th. The stock was bought at an average cost of $52.52 per share, with a total value of $393,900.00. Following the transaction, the chief executive officer now directly owns 430,569 shares in the company, valued at approximately $22,613,483.88. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 9.20% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.